Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL
CzechiaStudy on the Safety and Tolerability of VGL101 for Adults with Adult-Onset Leukoencephalopathy
FranceIn short
Leukoencephalopathy is a group of rare but serious conditions affecting the brain's white matter — the protective covering of nerve cells. While some forms develop because of viral infections in people with weakened immune systems, others result from genetic changes. Understanding when and how these conditions are diagnosed can make a crucial difference in managing symptoms and slowing disease progression.
Knowing when to seek medical evaluation for leukoencephalopathy can be challenging because the early symptoms often appear subtle and may resemble other conditions. However, certain groups of people should be particularly alert to changes in their health and consider diagnostic testing sooner rather than later.
People with weakened immune systems face the highest risk of developing one form of this condition called Progressive Multifocal Leukoencephalopathy, or PML. This includes individuals living with HIV/AIDS, those undergoing treatment for certain cancers like leukemia or lymphoma, and people who have received organ transplants and take medications to prevent rejection. Additionally, individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, or lupus — especially those taking certain biological therapies — should remain vigilant about neurological symptoms.
The first signs that warrant medical attention typically include clumsiness, difficulty coordinating movements, unexplained weakness, or changes in how you speak or think. These symptoms may start so gradually that you barely notice them at first. Some people experience personality changes that family members notice before the affected person does. In children with genetic forms of leukoencephalopathy, parents might observe delayed motor skills like crawling or walking, though many children appear completely normal at birth.
Anyone taking immunosuppressive or immunomodulatory medications — drugs that alter how the immune system works — should discuss with their doctor whether they need regular monitoring. This is especially important for people taking natalizumab (used for multiple sclerosis) or rituximab (used for various conditions), as these medications have been associated with increased PML risk.
Diagnosing leukoencephalopathy requires a combination of clinical evaluation, imaging studies, and laboratory tests. Doctors use multiple approaches because no single test can definitively confirm all forms of this condition, and distinguishing between different types is essential for proper management.
The diagnostic journey typically begins with a thorough physical examination. Your healthcare provider will check your symptoms carefully and ask detailed questions about your medical history. They want to understand when symptoms started, how they've progressed, and whether you have any underlying conditions that might weaken your immune system. This conversation helps them determine which diagnostic tests will be most helpful.
Magnetic resonance imaging, or MRI, is the most important diagnostic tool for detecting leukoencephalopathy. This imaging technique uses powerful magnets and radio waves to create detailed pictures of your brain's internal structures. Unlike X-rays, MRI scans don't use radiation, making them safer for repeated use.
During the scan, the MRI machine can detect characteristic patterns of damage in the brain's white matter. These patterns appear as bright spots or regions called lesions on the scan images. Different types of leukoencephalopathy create distinct patterns that help doctors identify which form you might have. For Progressive Multifocal Leukoencephalopathy, the MRI typically shows multiple areas of white matter damage scattered throughout different parts of the brain, which is why it's called "multifocal."
In some cases involving genetic forms of leukoencephalopathy, MRI changes may be visible even before symptoms appear. For instance, with leukoencephalopathy with vanishing white matter, specific changes in the brain can be seen on MRI that are characteristic of this condition, helping doctors make the diagnosis earlier.
A spinal tap, also called a lumbar puncture, is a procedure where doctors collect a small sample of cerebrospinal fluid — the liquid that surrounds and cushions your brain and spinal cord. During this procedure, a thin needle is inserted into the lower back to withdraw the fluid. While this might sound uncomfortable, doctors use local anesthesia to minimize discomfort.
The cerebrospinal fluid sample is then tested in a laboratory. For Progressive Multifocal Leukoencephalopathy, lab technicians use a technique called polymerase chain reaction, or PCR, to detect the genetic material (DNA) of the JC virus in the fluid. The JC virus, named after the initials of the first person identified with it (John Cunningham), causes PML. Finding this virus's DNA in your cerebrospinal fluid provides strong evidence of PML, especially when combined with characteristic MRI findings and progressive symptoms.
Blood testing plays several important roles in diagnosing leukoencephalopathy. For Progressive Multifocal Leukoencephalopathy, doctors can perform a blood test to detect antibodies to the JC virus. Antibodies are proteins your body makes when exposed to an infection. Between 40 and 90 percent of the general population have been exposed to JC virus at some point, usually during childhood, though most people never develop symptoms because healthy immune systems keep the virus under control.
If you're about to start treatment with certain medications known to increase PML risk — particularly natalizumab — your doctor will typically order this antibody test before beginning therapy. The test shows not only whether you have JC virus antibodies but also the level of these antibodies in your blood, which helps estimate your risk of developing PML. Even if your initial test is negative, doctors recommend repeating it every six months because you could become infected with JC virus at any time.
For genetic forms of leukoencephalopathy, different blood tests may be ordered. Genetic testing can identify mutations in specific genes that cause conditions like leukoencephalopathy with vanishing white matter. This condition results from mutations in five genes that provide instructions for making a protein important for regulating protein production in cells.
In rare situations where other diagnostic methods don't provide clear answers, doctors may recommend a brain biopsy. This procedure involves surgically removing a tiny sample of brain tissue for examination under a microscope. A brain biopsy is considered the most definitive way to diagnose PML, as it allows pathologists to directly observe the damage to cells that produce myelin — the fatty protective covering around nerve fibers — and potentially identify the virus within these cells.
However, because brain biopsies are invasive procedures that carry risks, doctors typically reserve them for cases where the diagnosis remains uncertain despite other tests. Most of the time, the combination of progressive symptoms, characteristic MRI findings, and detection of JC virus DNA in cerebrospinal fluid is sufficient to diagnose PML without needing a biopsy.
While MRI remains the preferred imaging method, doctors occasionally use computed tomography, or CT scans, particularly when MRI isn't available or cannot be performed. CT scans use X-rays to create cross-sectional images of the brain. They can detect lesions in the white matter, though they're generally less detailed than MRI scans for this purpose.
Some medical centers may also use electroencephalogram, or EEG, testing, which measures electrical activity in the brain. While not specific for leukoencephalopathy, EEG results can provide additional information about brain function that supports the diagnosis when combined with other tests.
When patients with leukoencephalopathy consider participating in clinical trials testing new treatments, they typically undergo additional diagnostic evaluations beyond standard clinical testing. These assessments help researchers ensure that participants truly have the condition being studied and establish baseline measurements to track whether experimental treatments work.
Clinical trials for Progressive Multifocal Leukoencephalopathy usually require confirmed diagnosis through multiple methods. Participants generally need documented evidence of JC virus in their cerebrospinal fluid using PCR testing, along with MRI scans showing characteristic white matter lesions consistent with PML. Many trials also require baseline neurological examinations that carefully measure and document the extent of symptoms and disabilities before treatment begins.
Researchers conducting clinical trials typically perform more frequent imaging studies than in routine clinical care. Instead of having MRI scans only when symptoms change, trial participants might receive scans at regular intervals — perhaps every few weeks or months — to precisely track changes in brain lesions. This frequent monitoring helps researchers determine whether experimental treatments slow disease progression, stop it, or allow improvement.
Blood tests in clinical trials often go beyond the standard antibody tests used in clinical practice. Researchers may measure immune system cell counts and function in great detail to understand how experimental treatments affect the immune response against JC virus. Some trials specifically look at T-cells, specialized immune cells that attack virus-infected cells. Understanding whether treatments boost T-cell responses against JC virus helps scientists develop more effective therapies.
For trials investigating treatments for genetic forms of leukoencephalopathy, genetic testing confirmation is essential. Researchers need documented proof of specific gene mutations to ensure participants have the exact condition the trial is designed to treat. This might involve sending blood samples to specialized laboratories that perform detailed genetic analysis.
Some innovative clinical trials exploring new therapeutic approaches like T-cell adoptive transfer — where immune cells are collected, potentially modified, and returned to the patient — or immune checkpoint inhibitor therapies require even more specialized diagnostic testing. These trials may involve removing and analyzing immune cells from participants' blood to determine whether their cells can be effectively used in these experimental treatments.
Clinical trials also typically assess quality of life and functional abilities through standardized questionnaires and neurological assessments. These measurements help researchers understand not just whether treatments affect brain lesions on MRI scans, but whether they meaningfully improve patients' daily lives and abilities to perform everyday tasks.
The outlook for people with leukoencephalopathy varies considerably depending on which specific form they have and what underlying condition led to its development. For Progressive Multifocal Leukoencephalopathy, the prognosis depends heavily on whether the immune system can be restored to fight the JC virus infection. People whose PML developed because of HIV/AIDS generally have better outcomes if they begin antiretroviral therapy promptly, with as many as half surviving, though they may experience ongoing neurological problems. Those who develop PML while taking immunosuppressive medications may recover if the medication is stopped quickly, though many continue having difficulties related to the infection even after recovery.
Unfortunately, PML typically progresses over several weeks to months, with symptoms steadily worsening. The disease causes increasing disability that can become life-threatening. However, the progression isn't always steady — some people experience periods of relative stability interrupted by episodes of rapid decline, particularly when triggered by stress, infections, or injuries.
For genetic forms like leukoencephalopathy with vanishing white matter, the prognosis also varies. Childhood-onset forms typically progress more rapidly than those beginning in adolescence or adulthood. Progression tends to be uneven, with relatively stable periods followed by sudden worsening often triggered by infections, fevers, minor head injuries, or severe fright. These stresses can cause affected individuals to become lethargic or even fall into a coma.
Survival statistics for Progressive Multifocal Leukoencephalopathy paint a sobering picture. Death commonly occurs within one to nine months after symptoms begin. Historical data shows that approximately 80 percent of people with PML die within six months to a year following diagnosis. However, these statistics include cases from before modern antiretroviral therapy became available for HIV/AIDS, which has significantly improved outcomes for that group.
Among people living with HIV who develop PML, current antiretroviral therapy has dramatically changed survival rates. Studies estimate that with effective treatment restoring immune function, as many as half of people with HIV-associated PML now survive, representing a major improvement over earlier eras. However, survival doesn't always mean complete recovery, as many survivors continue experiencing neurological difficulties.
For people who develop PML while taking immunomodulatory medications like natalizumab for multiple sclerosis, stopping the medication and using plasma exchange to remove it from the bloodstream quickly may improve survival chances. Some individuals in this group recover once the medication is removed from their system, though many face ongoing challenges from brain damage that occurred before treatment was stopped.
A few individuals with PML survive longer than the typical nine-month timeframe, sometimes living about two years or more. These longer-term survivors represent cases where immune function was successfully restored before irreversible brain damage became too extensive. The outlook ultimately depends on the severity of the underlying condition that weakened the immune system and how well that condition responds to treatment.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
